US · CGEN · BIOTECHNOLOGY
Compugen Ltd. (CGEN) intrinsic value and stock valuation
$1.84as of 2026-11-21 · Mkt cap 215.58M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Compugen Ltd. DCF and intrinsic value
InvestorsCraft values CGEN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CGEN’s statements →
Compugen Ltd. Graham Number
Graham Number: $3.06d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Nuvectis Pharma, Inc. (NVCT) $19.39
- Tonix Pharmaceuticals Holding Corp. (TNXP) $2.38
- Corbus Pharmaceuticals Holdings, Inc. (CRBP) $2.06
- Innate Pharma S.A. (IPHA) $0.86
- Molecular Partners AG (MOLN) $2.53
- Milestone Pharmaceuticals Inc. (MIST) $0.37
- Cardiff Oncology, Inc. (CRDF) $0.85
- Rani Therapeutics Holdings, Inc. (RANI) $0.51
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $72.8M | $27.9M | $33.5M | $7.5M | $6M |
| Operating income | $31.3M | -$-14.89M | -$-12.99M | -$-35.37M | -$-35.07M |
| Net income | $35.3M | -$-14.23M | -$-18.75M | -$-33.69M | -$-34.2M |
| EPSd | $376.7K | -$-158.94K | -$-213.97K | -$-389.21K | -$-406.18K |
| Operating cash flow | $31.6M | $49.6M | -$-35.89M | -$-34.51M | -$-22.75M |
| Capital expenditure | -$-310K | -$-120K | -$-170K | -$-490K | -$-290K |
| Free cash flow | $31.3M | $49.5M | -$-36.06M | -$-34.99M | -$-23.04M |
| Total assets | $156.9M | $115M | $121.3M | $94.2M | $132.2M |
| Total debt | $2.96M | $2.91M | $1.35M | $1.93M | $2.75M |
| Net debt | -$-87.64M | -$-15.32M | -$-12.54M | -$-9.13M | -$-5.05M |
| Total equity | $102.7M | $54.9M | $65.6M | $77.7M | $106.7M |
| Cash and short-term investments | $145.6M | $103.3M | $50.7M | $83.4M | $117.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $72.8M | $27.9M | $33.5M | $7.5M | $6M |
| Cost of revenue | $9.25M | $7.93M | $2M | $970K | $680K |
| Gross profit | $63.5M | $19.9M | $31.5M | $6.53M | $5.32M |
| Research and development expenses | $22.8M | $24.8M | $34.5M | $30.7M | $28.7M |
| Selling, general and administrative expenses | $9.43M | $10M | $9.97M | $11.3M | $11.7M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $32.2M | $34.8M | $44.5M | $41.9M | $40.4M |
| Cost and expenses | $41.4M | $42.8M | $46.5M | $42.9M | $41.1M |
| Interest income | $4.41M | $5.24M | $3.24M | $1.44M | $890K |
| Interest expense | $0.00 | $30K | $30K | $30K | $30K |
| Depreciation and amortization | $470K | $490K | $480K | $480K | $460K |
| Ebitda | $35.9M | -$-9.19M | -$-9.28M | -$-33.13M | -$-33.72M |
| Operating income | $31.3M | -$-14.89M | -$-12.99M | -$-35.37M | -$-35.07M |
| Total other income/expenses, net | $4.07M | $5.18M | $3.21M | $1.74M | $870K |
| Income before tax | $35.4M | -$-9.71M | -$-9.78M | -$-33.64M | -$-34.2M |
| Income tax expense | $50K | $4.52M | $8.97M | $60K | $0.00 |
| Net income | $35.3M | -$-14.23M | -$-18.75M | -$-33.69M | -$-34.2M |
| Weighted average shares outstanding | $93.4M | $89.5M | $87.6M | $86.6M | $84.2M |
| Weighted average diluted shares outstanding | $93.8M | $89.5M | $87.6M | $86.6M | $84.2M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $145.6M | $103.3M | $50.7M | $83.4M | $117.1M |
| Net receivables | $290K | $270K | $61.3M | $320K | $190K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $148M | $106M | $114.6M | $86.1M | $123.2M |
| Property, plant and equipment, net | $3.2M | $3.69M | $2.54M | $3.36M | $3.9M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $410K | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $8.85M | $9M | $6.75M | $8.05M | $8.94M |
| Total assets | $156.9M | $115M | $121.3M | $94.2M | $132.2M |
| Accounts payable | $2.35M | $1.84M | $3.5M | $1.77M | $4.62M |
| Short-term debt | $520K | $450K | $630K | $610K | $770K |
| Deferred revenue | $11M | $9.63M | $11.2M | $0.00 | $0.00 |
| Total current liabilities | $22.6M | $20.2M | $26.3M | $11.9M | $17.1M |
| Long-term debt | $2.44M | $2.46M | $720K | $1.31M | $1.98M |
| Deferred revenue, non-current | $24.9M | $34.1M | $25.4M | $0.00 | $0.00 |
| Total non-current liabilities | $31.6M | $39.9M | $29.5M | $4.58M | $8.37M |
| Capital lease obligations | $2.96M | $2.91M | $1.35M | $1.93M | $2.75M |
| Total liabilities | $54.1M | $60.1M | $55.8M | $16.5M | $25.5M |
| Common stock | $260K | $250K | $250K | $240K | $240K |
| Retained earnings | -$-453.42M | -$-488.76M | -$-474.53M | -$-455.77M | -$-422.08M |
| Accumulated other comprehensive income (loss) | $10K | $10K | $0.00 | $0.00 | $0.00 |
| Total equity | $102.7M | $54.9M | $65.6M | $77.7M | $106.7M |
| Total investments | $55.5M | $85M | $36.8M | $72.3M | $109.3M |
| Total debt | $2.96M | $2.91M | $1.35M | $1.93M | $2.75M |
| Net debt | -$-87.64M | -$-15.32M | -$-12.54M | -$-9.13M | -$-5.05M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $35.3M | -$-14.23M | -$-18.75M | -$-33.69M | -$-34.2M |
| Depreciation and amortization | $470K | $490K | $480K | $480K | $460K |
| Stock-based compensation | $0.00 | $3.02M | $3.55M | $4.33M | $4.28M |
| Change in working capital | -$-5.35M | $62.1M | -$-20.71M | -$-5.55M | $6.82M |
| Accounts receivable | $360K | $59.9M | -$-61.11M | $3.04M | $2M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | -$-3.37M |
| Accounts payable | $520K | -$-4.41M | $3.51M | -$-1.6M | $3.37M |
| Net cash provided by operating activities | $31.6M | $49.6M | -$-35.89M | -$-33.92M | -$-23.22M |
| Investments in property, plant and equipment | -$-310K | -$-120K | -$-170K | -$-490K | -$-290K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $30M | -$-46.25M | $35.5M | $37.1M | $6.62M |
| Common stock issued | $10.6M | $540K | $3.08M | $350K | $15M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $10.6M | $550K | $3.08M | $350K | $16.8M |
| Net change in cash | $72.4M | $3.97M | $2.83M | $2.91M | $700K |
| Cash at end of period | $90.6M | $18.2M | $14.3M | $11.4M | $8.51M |
| Operating cash flow | $31.6M | $49.6M | -$-35.89M | -$-34.51M | -$-22.75M |
| Capital expenditure | -$-310K | -$-120K | -$-170K | -$-490K | -$-290K |
| Free cash flow | $31.3M | $49.5M | -$-36.06M | -$-34.99M | -$-23.04M |
Line items
Line items
Line items
About Compugen Ltd.
Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701, an anti-PVRIG antibody currently undergoing Phase I clinical studies for solid tumors. COM902, a therapeutic antibody designed to target TIGIT, which is also in Phase I clinical trials as a monotherapy for advanced malignancies. Bapotulimab, an antibody targeting ILDR2, presently in Phase I clinical development for solid tumor indications. AZD2936, an innovative bispecific antibody targeting both TIGIT and PD-1, advancing through Phase I/II clinical studies for patients with advanced or metastatic non-small cell lung cancer. Additionally, Compugen maintains earlier-stage immuno-oncology programs, with a particular emphasis on myeloid targets. To further its research and development, Compugen actively fosters strategic alliances. It has a collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics that modulate immune checkpoint regulators. Another key partnership is with Bristol-Myers Squibb, aimed at evaluating the safety and tolerability of COM701 when administered alongside Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in patients with advanced solid tumors. The company also collaborates with Johns Hopkins School of Medicine to investigate novel T cell and myeloid checkpoint targets, and has a distinct research collaboration with Johns Hopkins University specifically dedicated to myeloid science. Furthermore, Compugen holds a licensing agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products.
- CEO
- Eran Ophir
- Employees
- 75
- Beta
- 2.77
Explore
Frequently asked questions
What is the intrinsic value of Compugen Ltd. (CGEN)?
InvestorsCraft does not currently publish an intrinsic value for CGEN. How the IC value is calculated.
Is CGEN undervalued?
InvestorsCraft does not publish an undervaluation signal for CGEN at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.